ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results
by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.